La base de datos GLP-1

Perfiles completos y basados en evidencia para cada medicamento aprobado por la FDA para perder peso.

Ozempic

(semaglutide)

Aprobado para: Pérdida de peso y diabetes tipo 2

Ozempic is a once-weekly injectable GLP-1 receptor agonist approved for type 2 diabetes, widely used off-label for weigh…

Novo Nordisk

(semaglutide)

Aprobado para: Pérdida de peso

Wegovy is a higher-dose semaglutide injection specifically approved for chronic weight management in adults with obesity…

Novo Nordisk

(tirzepatide)

Aprobado para: Pérdida de peso y diabetes tipo 2

Mounjaro is a once-weekly dual GIP/GLP-1 receptor agonist approved for type 2 diabetes, with significant weight loss eff…

Eli Lilly

(tirzepatide)

Aprobado para: Pérdida de peso

Zepbound is a tirzepatide injection specifically approved for chronic weight management, offering the same dual-action m…

Eli Lilly

(liraglutide)

Aprobado para: Pérdida de peso

Saxenda is a daily injectable GLP-1 receptor agonist approved for chronic weight management, an earlier-generation alter…

Novo Nordisk

(naltrexone-bupropion)

Aprobado para: Pérdida de peso

Contrave is an oral combination of naltrexone and bupropion approved for chronic weight management, targeting appetite a…

Currax Pharmaceuticals